| scholarly article | Q13442814 |
| P50 | author | Kenneth C. Anderson | Q28421846 |
| Paul G. Richardson | Q87712102 | ||
| Nikhil V Munshi | Q89228014 | ||
| Teru Hideshima | Q114455520 | ||
| Dharminder Chauhan | Q117224711 | ||
| Constantine S Mitsiades | Q117224720 | ||
| Laurence P Catley | Q117224725 | ||
| Nicholas S Mitsiades | Q117224764 | ||
| Reshma Shringarpure | Q117224785 | ||
| P2093 | author name string | Richard LeBlanc | |
| Renate Burger | |||
| Puneet Cheema | |||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1787-1790 | |
| P577 | publication date | 2003-09-25 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Immunomodulatory drug costimulates T cells via the B7-CD28 pathway | |
| P478 | volume | 103 |
| Q33421680 | A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer |
| Q35848744 | A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma |
| Q36822868 | A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma |
| Q39045586 | Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities |
| Q40429629 | Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs |
| Q41818550 | Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone? |
| Q21285161 | Biological activity of lenalidomide and its underlying therapeutic effects in multiple myeloma |
| Q41728843 | CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma |
| Q35828826 | CD28-mediated regulation of multiple myeloma cell proliferation and survival |
| Q36546548 | CD4⁺ T cells play a crucial role for lenalidomide in vivo anti-tumor activity in murine multiple myeloma |
| Q38062038 | Can we change the disease biology of multiple myeloma? |
| Q38779858 | Carfilzomib alters the HLA-presented peptidome of myeloma cells and impairs presentation of peptides with aromatic C-termini. |
| Q37983913 | Chemokine-dependent B cell-T cell interactions in chronic lymphocytic leukemia and multiple myeloma - targets for therapeutic intervention? |
| Q37902948 | Chronic lymphocytic leukemia: an update on biology and treatment. |
| Q35322473 | Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma |
| Q36252792 | Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer |
| Q35784505 | Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets |
| Q38530066 | Clinical utility and patient consideration in the use of lenalidomide for multiple myeloma in Chinese patients |
| Q38155039 | Coinhibitory molecule PD-1 as a potential target for the immunotherapy of multiple myeloma |
| Q37764870 | Cost-effectiveness of lenalidomide in multiple myeloma. |
| Q36376450 | Current therapeutic uses of lenalidomide in multiple myeloma |
| Q38110935 | Dendritic cells in myelodysplastic syndromes: from pathogenesis to immunotherapy. |
| Q28066890 | Development of Novel Immunotherapies for Multiple Myeloma |
| Q36304004 | Drug insight: thalidomide as a treatment for multiple myeloma |
| Q37773257 | Drug-mediated and cellular immunotherapy in multiple myeloma |
| Q41877240 | Dysfunctional T regulatory cells in multiple myeloma |
| Q28241744 | Early experience with novel immunomodulators for cancer treatment |
| Q92722336 | Elevated eosinophil level predicted long time to next treatment in relapsed or refractory myeloma patients treated with lenalidomide |
| Q30353154 | Emerging drugs for chronic lymphocytic leukaemia. |
| Q44599389 | Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide |
| Q24685895 | Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications |
| Q37142367 | Epigenetic induction of adaptive immune response in multiple myeloma: sequential azacitidine and lenalidomide generate cancer testis antigen-specific cellular immunity |
| Q35592305 | Expanding role of lenalidomide in hematologic malignancies |
| Q36154837 | Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs |
| Q89726615 | Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma |
| Q34257912 | Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. |
| Q35033514 | Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia |
| Q26865561 | Immune reconstitution in chronic lymphocytic leukemia |
| Q36904977 | Immunodeficiency and immunotherapy in multiple myeloma |
| Q92407035 | Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS |
| Q54204985 | Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities. |
| Q39138108 | Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience |
| Q90835733 | Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways |
| Q27001318 | Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia |
| Q34325722 | Immunomodulatory drugs in multiple myeloma |
| Q37991783 | Immunomodulatory drugs in multiple myeloma: from molecular mechanisms of action to clinical practice |
| Q40053620 | Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo |
| Q34369823 | Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma |
| Q54213159 | Impact of lenalidomide maintenance on the immune environment of multiple myeloma patients with low tumor burden after autologous stem cell transplantation. |
| Q37945305 | Intrinsic modulation of lymphocyte function by stromal cell network: advance in therapeutic targeting of cancer |
| Q51709036 | Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells. |
| Q37275289 | Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3(+)CD8(+) T cells against Various Solid Tumors |
| Q34009041 | Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia |
| Q33903133 | Lenalidomide enhances anti-myeloma cellular immunity |
| Q39654887 | Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers |
| Q39798588 | Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells. |
| Q37012554 | Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro |
| Q38829322 | Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses |
| Q36090011 | Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas |
| Q30249007 | Lenalidomide for the treatment of B-cell lymphoma |
| Q33403183 | Lenalidomide for the treatment of relapsed and refractory multiple myeloma. |
| Q38010055 | Lenalidomide in solid tumors |
| Q36125070 | Lenalidomide in the treatment of chronic lymphocytic leukemia. |
| Q37626685 | Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma |
| Q35844148 | Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients |
| Q34137016 | Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53 |
| Q47112048 | Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28- T-cells |
| Q38758162 | Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications |
| Q52577558 | Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma. |
| Q36806619 | Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses |
| Q37334965 | Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia |
| Q37791617 | Lenalidomide: a synthetic compound with an evolving role in cancer management |
| Q36731534 | Lenalidomide: immunomodulatory, antiangiogenic, and clinical activity in solid tumors |
| Q30235355 | Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends |
| Q37734280 | Mechanism of action of immunomodulatory agents in multiple myeloma |
| Q24605861 | Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma |
| Q21198872 | Mechanism of action of lenalidomide in hematological malignancies |
| Q35171777 | Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma |
| Q38551337 | Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma |
| Q90505125 | Microfluidic assembly of hydrogel-based immunogenic tumor spheroids for evaluation of anticancer therapies and biomarker release |
| Q36498784 | Model of translational cancer research in multiple myeloma |
| Q39570166 | Molecular action of lenalidomide in lymphocytes and hematologic malignancies |
| Q38035044 | Molecular mechanisms of effectiveness of novel therapies in multiple myeloma |
| Q40473651 | Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. |
| Q37815266 | Multiple myeloma: biology of the disease |
| Q37340304 | Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders |
| Q37691759 | Novel agents for B-cell non-Hodgkin lymphoma: science and the promise |
| Q37822742 | Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma. |
| Q35558057 | Novel and emerging targeted-based cancer therapy agents and methods |
| Q38069614 | Novel immunomodulatory compounds in multiple myeloma |
| Q26770391 | Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic) |
| Q38164818 | Novel investigational agents for the treatment of scleroderma |
| Q36871990 | Novel therapeutic targets in mantle cell lymphoma |
| Q34636002 | Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm |
| Q33429608 | Phase I clinical trial of lenalidomide in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced cancer |
| Q34666866 | Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. |
| Q33436535 | Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints |
| Q36998210 | Preclinical studies of novel targeted therapies |
| Q36274133 | Preferential enhancement of older human T cell cytokine generation, chemotaxis, proliferation and survival by lenalidomide |
| Q38462720 | Prognostic indicators of lenalidomide for multiple myeloma: consensus and controversy |
| Q43250303 | Prognostically significant cytotoxic T cell clones are stimulated after thalidomide therapy in patients with multiple myeloma |
| Q33398019 | Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers |
| Q38006901 | T-regulatory cells: key players in tumor immune escape and angiogenesis |
| Q37431609 | Targeted therapies in multiple myeloma |
| Q38853857 | Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma |
| Q36965455 | Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia |
| Q34775475 | Thalidomide and lenalidomide: Mechanism-based potential drug combinations |
| Q80406975 | Thalidomide for rheumatic disease: the best of both worlds? |
| Q39600474 | Thalidomide has anti-inflammatory properties in neonatal immune cells |
| Q38074017 | Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. |
| Q36612543 | The emerging role of lenalidomide in the management of lymphoid malignancies |
| Q44824886 | The evolution of thalidomide and its IMiD derivatives as anticancer agents |
| Q36739807 | The evolving role of lenalidomide in the treatment of hematologic malignancies |
| Q99211979 | The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models |
| Q38749362 | The safety of pomalidomide for the treatment of multiple myeloma |
| Q35097319 | The use of novel agents in the treatment of relapsed and refractory multiple myeloma |
| Q36613990 | Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma |
| Q37958036 | Treating chronic lymphocytic leukemia with thalidomide and lenalidomide |
| Q38791007 | Treatment of Multiple Myeloma in a Heart Transplant Recipient |
| Q37176044 | Treatment of plasma cell dyscrasias with lenalidomide |
| Q42737828 | Trial Watch: Lenalidomide-based immunochemotherapy |
| Q34253548 | Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies |
| Q40382947 | p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma |
Search more.